Protective effect of omeprazole on gastric mucosal of cirrhotic portal hypertension rats

Wei Gao¹, Hai-Ying Li¹, Li-Xin Wang¹, Li-Jun Hao¹, Jian-Li Gao¹, Rong-Juan Zheng¹, Chun-Jiang Cai²*, Yan-Ling Si¹*

¹Department of Gastroenterology, Tangshan Workers’ Hospital, Tangshan 063000, China
²Department of Spleen and Stomach, Tangshan TCM Hospital, Tangshan 063003, China

ARTICLE INFO

Objective: To observe the protective effect of omeprazole on gastric mucosal of cirrhotic portal hypertension rats. Methods: All rats were randomly divided into normal control group, cirrhosis and treatment group. Thioacetamide was used to establish rat model of cirrhotic portal hypertension. The necrotic tissue of gastric mucosa ulcer focus, degree of neutrophils infiltration at the ulcer margin, portal pressure, portal venous flow, abdominal aortic pressure, abdominal aortic blood flow at front end, gastric mucosal blood flow (GMBF), glycoprotein (GP) of gastric mucosa, basal acid secretion, H⁺ back-diffusion, gastric mucosal damage index, NO, prostaglandin E₂ (PGE₂) and tumor necrosis factor–α (TNF–α) were determined respectively, and the pathological changes of gastric mucosa were also observed by microscope. Results: Compared with cirrhosis group and the control group, the ulcer bottom necrotic material, gastric neutrophil infiltration and UI of the treatment group were all decreased significantly (P<0.01), GMBF value, GP values, serum NO, PGE₂, TNF–α were all significantly increased. Conclusions: Omeprazole has an important protective effect on gastric mucosal and it can increase gastric mucosal blood flow and related to many factors.

1. Introduction

Portal hypertension gastropathy (PHG) of cirrhotic has become a main clinical manifestations of the decompensated cirrhosis in clinical. It threatens life because of the high incidence of gastric mucosal bleeding. Omeprazole is one of the most common drugs to treat gastric mucosal lesion. Its significant inhibition effect on the gastric acid secretion has been very clear, but the protective effect on gastric mucosal is still unclear. This study is to explore the protective effect of omeprazole on gastric mucosal of cirrhotic portal hypertension rats, and the possible mechanisms.

2. Materials and methods

2.1. Animals and grouping

A total of 30 6–week–old male SD rats were selected, weighting 200–220 g, which were purchased from Experimental Animal Department, XX University. The animals were randomly divided into three groups, including the normal control group (n=10), cirrhosis group (n=10), treatment group (n=10). If rats died or abandoned during the study, they were supplemented again. All rats were fed by standards pellet then kept under constant humidity and temperature.

2.2. Reagents and instruments

0.03% thioacetamide (TAA), omeprazole capsules 20 mg
were purchased from Haikou Qili Pharmaceutical Co., Ltd. Rat prostaglandin E₂ (PGE₂), tumor necrosis factor-α (TNF-α) ELISA kit were purchased from Wuhan Boster Reagent Company. Optical microscopy, laser doppler flowmeter, digital millivoltmeter, electronic scales, micro adding sample appliance, etc. were provided by the laboratory.

2.3. Model establishment

Rats in the normal control group received 25 mg/kg ketamine under intraperitoneal anesthesia, draped in a sterile manner. They were opened layers by layers and the left suprarenal vein was isolated without special intervention. After adequate hemostasis, they were sutured layers by layers. Animals received water after operation. Rats in the cirrhosis group and treatment group underwent double ligation after left suprarenal vein fully exposed. If there was a branch of small blood vessels, the vessels were also ligated together, then were sutured after hemostasis. The rats received concentration of 0.03% TAA solution as drinking water. Body weight was monitored, and was maintained between 200–260 g. If the margin of body weight increase was more than 20 g or decrease more than 10 g in one week, then concentration of TAA was increased or decreased by 50%. All rats were continuously fed for 14 weeks, then the treatment was stopped for two weeks. After three days of molding, the treatment group were fed by omeprazole 15 mg/kg • d one time everyday. The sampling was performed after 2 weeks.

2.4. Indexes observation

2.4.1. Hemodynamic index detection

Using laser doppler flowmeter, free portal pressure (FPP), portal venous flow (PVF), abdominal aortic pressure (AAP) and abdominal aorta blood flow (AAF) at the beginning point was measured. Greater and lesser curvatures of gastric body, greater and lesser curvatures of gastric antrum on the surface of gastric mucosa were also measured. The average value were obtained as gastric mucosal blood flow (GMBF).

2.4.2. Glycoprotein (GP) of gastric

Mucus were scraped on the surface of mucosa in gastric gland area and weighed. Glycoprotein content was measured by Coomassie brilliant blue method.

2.4.3. Basal acid secretion (BAS)

Gastral cavity was washed with normal saline. The beginning part of the duodenum was intubated and the duodenum was ligated. One mL/min saline was added with uniform injection pump, the remote casing was open once every 10 mins for 6 times. H⁺ concentration was measured by 0. 2 mol/L NaOH microtitration and the average value were obtained.

2.4.4. H⁺ back diffusion (H⁺ BD)

Gastral cavity was washed with sarfeh solution (100 mmol/L HCl and 50 mmol/L NaCl). The duodenum was ligated. Sarfeh solution was injected at 3 mL/times, 20 min/times for 3 times. H⁺ concentration was also measured by microtitration. The value was obtained by minusing Sarfeh fluid H⁺ concentration.

2.4.5. Index of gastric mucosal lesion

Stomach tissue was removed, cut and flattened. The score was calculated by Guth standard. Spot–like erosions was 1, erosion <1 mm was 2, erosion between 1 –2 mm was 3, erosion between 2–4 mm was 4, erosion> 4 mm was 5.

2.4.6. Histological observation

The gastric tissues were fixed, paraffin routinely embedded, sectioned, and HE stained. Necrotic status and neutrophil infiltration was observed under light microscope, Judgement standard was as follows: No necrotic material or neutrophil infiltration was 0; A few necrotic material and neutrophil infiltration at the bottom edge of the ulcer was 1; Thick layer of necrotic at the ulcer floor and obvious neutrophil infiltration at the marginal tissue of ulcer was 3; Between them was 2.

2.4.7. Serum NO, PGE₂, TNF–α measurment

Venous blood samples were collected before the rats were sacrificed. After centrifugation, the serum NO content was measured. The serum PGE₂, TNF–α levels were measured by radioimmunoassay.

2.5. Statistical analysis

The data was analyzed with SPSS 13.0 software. Data were expressed as mean±SD. Homogeneity of variance was carried out for the measurement material, and multiple comparison was used if there is significant differences. P<0.05 was considered as statistical significance.

3. Results

3.1. Mucosa observation

The gross specimen of gastric in normal control rats showed smooth and complete surface. Microscope showed glands arranged regularly. Gross specimen of cirrhotic rats gastric showed obvious hyperemia and edema, one or more strip–shaped erosion and hemorrhagic focus, necrotic
material. Microscope showed glandular arranged in disorder, great number of neutrophils infiltration, even involving in the serous layer. Gross specimen of gastric mucosal in the treatment group was with more complete structure. It also showed some hemorrhagic spot or hemorrhagic focus, but was decreased significantly than that in the cirrhosis group. Amount of necrotic material at the bottom of the ulcer was also less than that in the cirrhosis group. Microscope showed glandular arranged in order, a little neutrophils infiltration which was less than that of cirrhosis group.

3.2. Gastric mucosal damage index (GMDI)

In the control group, there was no damage; the gastric mucosal damage index of cirrhotic rats was significantly increased. Compared with the control group and treatment group, the differences were significant \( P < 0.05 \). There was still some gastric mucosal injury in the treatment group, the damage index was significantly higher than the control group \( P < 0.05 \) (Table 1).

3.3. Hemodynamic score results

FPP and AAF index of the cirrhosis group and treatment group were significantly higher than that in the control group, which indicated successful cirrhosis model. The gastric GMBF of the cirrhosis group decreased significantly compared with the control group and the treatment group \( P < 0.05 \). The gastric GMBF of the treatment group was slightly lower than the normal group, but the difference had no statistically significant \( P > 0.05 \) (Table 2).

3.4. Measurement of mucosal glycoproteins and \( H^+ \)

GP in Cirrhosis group was significantly lower than the control group and treatment group \( P < 0.05 \). There was no significantly difference in BAS secretionamong three groups \( P > 0.05 \) (Table 3).

3.5. Serum NO, PGE2, TNF−α of humoral factors

PGE2 expression in the cirrhosis group and the treatment group decreased significantly compared with that in the controls \( P < 0.05 \). There was no significantly difference between the treatment group and the cirrhosis group \( P > 0.05 \). TNF−α expression in the cirrhosis group was significantly increased compared with that in the control group and the treatment group, \( P < 0.05 \); TNF−α expression

---

### Table 1

<table>
<thead>
<tr>
<th>Groups</th>
<th>Number of cases</th>
<th>Damage index</th>
<th>Necrotic tissue</th>
<th>Infiltration of neutrophils</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cirrhosis group</td>
<td>10</td>
<td>38.5±4.2*</td>
<td>2.8±1.0*</td>
<td>3.4±0.5*</td>
</tr>
<tr>
<td>Treatment group</td>
<td>10</td>
<td>8.8±1.1△</td>
<td>1.3±0.6△</td>
<td>1.6±0.6△</td>
</tr>
</tbody>
</table>

Note: * Compared with control group, \( P < 0.05 \); △ Compared with cirrhosis group, \( P < 0.05 \).

### Table 2

<table>
<thead>
<tr>
<th>Groups</th>
<th>FPP (kPa)</th>
<th>PVF (mL/min)</th>
<th>AAP (kPa)</th>
<th>AAF (mL/min)</th>
<th>GMBF (V/μV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>0.8±0.2</td>
<td>14.3±2.2</td>
<td>14.3±1.3</td>
<td>37.9±4.3</td>
<td>305.3±22.5</td>
</tr>
<tr>
<td>Cirrhosis group</td>
<td>1.5±0.4*</td>
<td>13.2±2.0</td>
<td>15.1±1.0</td>
<td>78.4±7.6*</td>
<td>179.6±18.7*</td>
</tr>
<tr>
<td>Treatment group</td>
<td>1.5±0.3*</td>
<td>13.6±2.1</td>
<td>15.3±1.2</td>
<td>79.5±6.8*</td>
<td>288.7±20.1△</td>
</tr>
</tbody>
</table>

Note: * Compared with control group, \( P < 0.05 \); △ Compared with cirrhosis group, \( P < 0.05 \).

### Table 3

<table>
<thead>
<tr>
<th>Groups</th>
<th>GP (mg)</th>
<th>BAS (μEq/h)</th>
<th>H+ BD (μEq/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>0.4±0.2</td>
<td>10.8±1.1</td>
<td>40.7±4.2</td>
</tr>
<tr>
<td>Cirrhosis group</td>
<td>0.2±0.1*</td>
<td>9.8±1.4</td>
<td>133.8±6.9*</td>
</tr>
<tr>
<td>Treatment group</td>
<td>0.4±0.2△</td>
<td>10.3±1.2</td>
<td>44.4±5.6△</td>
</tr>
</tbody>
</table>

Note: * Compared with control group, \( P < 0.05 \); △ Compared with cirrhosis group, \( P < 0.05 \).

### Table 4

<table>
<thead>
<tr>
<th>Groups</th>
<th>Number of cases</th>
<th>NO (μ mol/L)</th>
<th>PGE2 (mol/L)</th>
<th>TNF−α (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>10</td>
<td>9.3±2.9</td>
<td>354.8±38.5</td>
<td>0.4±0.1</td>
</tr>
<tr>
<td>Cirrhosis group</td>
<td>10</td>
<td>27.6±4.1*</td>
<td>262.4±30.6*</td>
<td>1.7±0.7*</td>
</tr>
<tr>
<td>Treatment group</td>
<td>10</td>
<td>40.4±5.3△</td>
<td>274.2±32.2*</td>
<td>1.0±0.3△</td>
</tr>
</tbody>
</table>

Note: * Compared with control group, \( P < 0.05 \); △ Compared with cirrhosis group, \( P < 0.05 \).
in treatment group was significantly higher than the control group \(P<0.05\). NO expression in the treatment group was significantly higher than that in the control group and the cirrhotic group \(P<0.05\); NO expression in the cirrhotic group was significantly higher than the control group \(P<0.05\) (Table 4).

4. Discussion

Cirrhosis is the late stage of various chronic liver diseases, portal hypertension is the main manifestation during this stage and all the complications have a severe influence on patients’ quality of life. Therefore, it becomes a research hotspot to protect the gastric mucosa under portal hypertension. According to the previous studies, abundant blood flow is the basis for maintaining normal mucosal function in the physiological state. After the formation of portal hypertension, a large number of visceral blood flow through the arteriovenous shunt and collateral circulation directly into the systemic circulation, makes mucosal capillary network in the ischemic state, which may lead to the occurrence of PHG. Omeprazole is one of the most important drugs as a proton pump inhibitor, how to reduce stomach acid secretion and protect the gastric mucosa became the focus of this study.

To observe whether omeprazole treatment have an impact on gastric mucosal ulceration, some studies by established an animal model of acute gastric mucosal injury. The result showed that omeprazole treatment has an important effect for acute gastric mucosal injury, and large doses are better than small doses, and that the proton pump inhibitors omeprazole can inhibit gastric acid secretion, \(H^+\) diffused from gastric parietal cells to mucosa significantly reduced, prompting the gastric PH value increased significantly. This study suggests that \(H^+\) BD significantly reduced, which is consistent with the above results. Omeprazole can significantly reduce mucosal cells acidification damage degree. Meanwhile, the study suggests that GP protein was significantly increased. GP as a glycoprotein of epithelial cells cover the mucosal surface and buffer the mechanical damage between the stomach, while also provide the attachment platform for the gastric mucosal barrier. It is considered that GP is an accurate and sensitive indicator which can reflect the gastric mucosa and also play an important role in anti-acid, resisting pepsin and prevent ulceration. GP’s increase can help to protect the integrity of the gastric mucosa. Studies suggest that during gastric mucosal injury, the GP decrease degree is consistent with the mucosal injury. Proton pump inhibitor can protect mucosa and benefit to the epithelial repair.

Animal experiments suggested that NO as an important radical in the blood can change the gastric mucosal blood flow, and the use of NOS inhibitors will increase gastric mucosal injury of animal. The increase of serum NO will lead to the increase of serum NOS and \(\text{iNOS}\), and also reduced \(\text{cNOS}\), thereby damage to the tissue. But there are also studies suggested that after the use of PPI drugs, gastric mucosal protective level was positively correlated with the NO, considered the mechanism is related to the influence of parietal cells \(H^+–K^+–\text{ATP}\) activity. This study suggests that NO of the omeprazole treatment group was significantly higher and the GMBF also increased. Maybe the NO vasodilatory effects can promote the increase of GMBF. Although NO free radical will damage the gastric mucosa tissue, NO may mediate the omeprazole’s protective effect on gastric mucosa after omeprazole inhibited \(H^+–K^+–\text{ATP}\) enzyme.

\(\text{PGE}_2\) is one of the major PGs of gastric, but experiments suggest that it can inhibit the apoptosis of rat gastric mucosa. It can increase the secretion of gastric epithelial mucus and the bicarbonate, also protect gastric mucosa to avoid any attack by various invasion factors, and have the same damage effect on the acid–ethanol. This study suggests that \(\text{PGE}_2\) significantly lower in cirrhotic rats, but the omeprazole treatment did not change significantly, \(\text{TNF}–\alpha\) as one of the inflammatory cytokines can strengthen tail lesions by increasing vascular permeability during the PHG. Studies suggest that \(\text{TNF}–\alpha\) content was significantly associated with the damage degree of toxic mucosal. It play an important role as the media factor of endotoxin–induced gastric mucosal injury, suggested that it can be used as early monitoring indicators for the clinical effect of gastric mucosal injury. This study suggests that the \(\text{TNF}–\alpha\) significantly increased in the cirrhosis group, but it can be effectively reduced after drug treatment. It may be due to the increase of TNF–\(\alpha\) can increase the local tissue inflammation, leading to mucosal ischemia and hypoxia, decreased gastric mucosal blood flow and increased blood sedimentation, and then increased the damage. This study suggests that the damage degree of gastric mucosal surfaces can be significantly reduced after omeprazole treatment, possibly because of many factors mentioned above.

In summary, we can speculate that omeprazole play a protective role in the gastric mucosa by improving the gastric environment, through the influence of inflammatory cytokines to slowdown its further damage the gastric mucosa. These results suggested that omeprazole have a protective effect on the cirrhotic portal hypertension induced gastric mucosal injury.

Conflict of interest statement

We declare that we have no conflict of interest.
References


